{"context": "The administration of vaccines is called vaccination\nVaccination is the most effective method of preventing infectious diseases; widespread immunity due to vaccination is largely responsible for the worldwide eradication of smallpox and the restriction of diseases such as polio measles and tetanus from much of the world\nAnd European Medical Organisation Also reports that licensed vaccines are available for twenty-five different preventable infections\nThe first recorded use of inoculation to prevent smallpox see variolation occurred in the 16th century in China with the earliest hints of the practice in China coming during the 10th century", "evidence": "The vaccine is administered.\nVaccination is the most effective method of preventing infectious diseases; widespread immunity due to vaccination is largely responsible for the worldwide eradication of smallpox.\nAccording to the World Health Organization, there are 25 different preventable infections that can be prevented with licensed vaccines.\nThe first recorded use of inoculation to prevent smallpox took place in China in the 16th century.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["vaccines is called", "prevent smallpox see", "practice in China"], "uv": ["worldwide eradication", "smallpox see variolation"]}, "hinfo": {"hp": "And European Medical Organisation Also", "pp": ["And European Medical Organisation Also", "The World Health Organization WHO"], "cp": ["The World Health Organization WHO reports that licensed vaccines are available for twenty-five different preventable infections", "And European Medical Organisation Also reports that licensed vaccines are available for twenty-five different preventable infections"], "sf": ["licensed vaccines", "The World Health Organization"], "hs": [[322, 360]]}, "hf": 1}
{"context": "Vaccination is the most effective method of preventing infectious diseases; widespread immunity due to vaccination is largely responsible for the worldwide eradication of smallpox and the restriction of diseases such as polio measles and tetanus from much of the world\nThe World Health Organization WHO reports that licensed vaccines are available for twenty-five different preventable infections\nThe first recorded use of surgery to prevent smallpox see variolation occurred in the 16th century in China with the earliest hints of the practice in China coming during the 10th century\nIt was also the first disease for which a vaccine was produced", "evidence": "Vaccination is the most effective method of preventing infectious diseases; widespread immunity due to vaccination is largely responsible for the worldwide eradication of smallpox.\nAccording to the World Health Organization, there are 25 different preventable infections that can be prevented with licensed vaccines.\nThe first recorded use of inoculation to prevent smallpox took place in China in the 16th century.\nThe first vaccine for a disease was produced for it.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["prevent smallpox see", "practice in China", "vaccine was produced"], "uv": ["worldwide eradication", "smallpox see variolation", "first disease"]}, "hinfo": {"hp": "surgery", "pp": ["surgery", "inoculation"], "cp": ["The first recorded use of inoculation to prevent smallpox see variolation occurred in the 16th century in China with the earliest hints of the practice in China coming during the 10th century", "The first recorded use of surgery to prevent smallpox see variolation occurred in the 16th century in China with the earliest hints of the practice in China coming during the 10th century"], "sf": ["The first recorded use", "variolation"], "hs": [[423, 430]]}, "hf": 1}
{"context": "The first recorded use of inoculation to prevent smallpox see variolation occurred in the 16th century in China with the earliest hints of the practice in China coming during the 10th century\nIt was also the first disease for which a vaccine was produced\nThe folk practice of inoculation against smallpox was brought from Turkey to Britain in 1721 by Queen Anne Jane ...", "evidence": "The first recorded use of inoculation to prevent smallpox took place in China in the 16th century.\nThe first vaccine for a disease was produced for it.\nLady Mary Wortley Montagu brought the practice of inoculation against smallpox from Turkey to Britain.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["prevent smallpox see", "practice in China", "vaccine was produced"], "uv": ["smallpox see variolation", "first disease", "brought from Turkey"]}, "hinfo": {"hp": "Queen Anne Jane ...", "pp": ["Queen Anne Jane ...", "Lady Mary Wortley Montagu"], "cp": ["The folk practice of inoculation against smallpox was brought from Turkey to Britain in 1721 by Lady Mary Wortley Montagu", "The folk practice of inoculation against smallpox was brought from Turkey to Britain in 1721 by Queen Anne Jane ..."], "sf": ["Mary Wortley Montagu", "inoculation"], "hs": []}, "hf": 1}
{"context": "It was also the first disease for which a vaccine was produced\nThe folk practice of inoculation against smallpox was brought from Turkey to Britain in 1721 by Lady Mary Wortley Montagu\nThe terms vaccine and vaccination are derived from Variolae vaccinae smallpox of the cow the term devised by John Smith who both developed the concept of vaccines and created the first vaccine to denote cowpox", "evidence": "The first vaccine for a disease was produced for it.\nLady Mary Wortley Montagu brought the practice of inoculation against smallpox from Turkey to Britain.\nThe term vaccine was created by Edward Jenner who created the first vaccine to protect against cowpox.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["vaccine was produced", "devised by Edward"], "uv": ["first disease", "brought from Turkey", "term devised", "denote cowpox", "Variolae vaccinae smallpox", "vaccination are derived"]}, "hinfo": {"hp": "John Smith", "pp": ["John Smith", "Edward Jenner"], "cp": ["The terms vaccine and vaccination are derived from Variolae vaccinae smallpox of the cow the term devised by Edward Jenner who both developed the concept of vaccines and created the first vaccine to denote cowpox", "The terms vaccine and vaccination are derived from Variolae vaccinae smallpox of the cow the term devised by John Smith who both developed the concept of vaccines and created the first vaccine to denote cowpox"], "sf": ["Variolae vaccinae smallpox", "vaccines"], "hs": [[294, 304]]}, "hf": 1}
{"context": "The terms vaccine and vaccination are derived from Variolae vaccinae smallpox of the cow the term devised by Edward Jenner who both developed the concept of vaccines and created the first vaccine to denote cowpox\nHe used the phrase in 1798 for the long title of his Inquiry into the Variolae vaccinae Known as the Cow Pox in which he described the protective effect of cowpox against smallpox\nIn 1881 to honor Emile Le Smith proposed that the terms should be extended to cover the new protective inoculations then being developed\nThe science of vaccine development and production is termed vaccinology\n Effectiveness There is overwhelming scientific consensus that vaccines are a very safe and effective way to fight and eradicate infectious diseases", "evidence": "The term vaccine was created by Edward Jenner who created the first vaccine to protect against cowpox.\nThe long title of his Inquiry into theVariolae vaccinae known as the Cow Pox was the phrase he used in 1798.\nThe terms should be extended to cover the new protective inoculations that are being developed, according to Louis Pasteur.\nvaccinology is the science of vaccine development and production.\nVaccines are a very safe and effective way to fight infectious diseases.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["devised by Edward", "Variolae vaccinae Known", "used the phrase", "Louis Pasteur proposed", "termed vaccinology", "eradicate infectious diseases"], "uv": ["term devised", "denote cowpox", "Variolae vaccinae smallpox", "vaccination are derived", "described the protective", "Jenner Louis Pasteur", "consensus that vaccines"]}, "hinfo": {"hp": "Emile Le Smith", "pp": ["Emile Le Smith", "Jenner Louis Pasteur"], "cp": ["In 1881 to honor Jenner Louis Pasteur proposed that the terms should be extended to cover the new protective inoculations then being developed", "In 1881 to honor Emile Le Smith proposed that the terms should be extended to cover the new protective inoculations then being developed"], "sf": ["the new protective inoculations", "the terms"], "hs": [[410, 424]]}, "hf": 1}
{"context": "When the virulent version of an agent is encountered the body recognizes the protein coat on the agent and thus is prepared to respond by first neutralizing the target agent before it can enter cells and secondly by recognizing and destroying infected cells before that agent can multiply to vast numbers\nIn 1958 there were 763094 cases of influenza in the United States; 552 deaths resulted\nAfter the introduction of new vaccines the number of cases dropped to fewer than 150 per year median of 56", "evidence": "When the virulent version of an agent is encountered the body is prepared to respond by first recognizing the target agent before it can enter the cells and then destroy them before they can spread.\nThere were 552 deaths from the disease in the United States.\nThere were fewer than 150 cases per year after the introduction of new vaccines.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["recognizes the protein", "thus is prepared", "per year median"], "uv": ["body recognizes", "destroying infected cells", "vast numbers", "protein coat"]}, "hinfo": {"hp": "influenza", "pp": ["influenza", "measles"], "cp": ["In 1958 there were 763094 cases of measles in the United States; 552 deaths resulted", "In 1958 there were 763094 cases of influenza in the United States; 552 deaths resulted"], "sf": ["the United States", "763094 cases"], "hs": [[340, 349]]}, "hf": 1}
{"context": "In early 2008 there were 64 suspected cases of measles\nFifty-four of those infections were associated with importation from another country although only thirteen percent were actually acquired outside the United States; 63 of the 64 individuals either had never been vaccinated against measles or were uncertain whether they had been vaccinated\nThe measles vaccine is estimated to prevent one thousand infections every year\nVaccines led to the eradication of smallpox one of the most contagious and deadly diseases in humans", "evidence": "There were 64 suspected cases of the disease in the first few months of 2008.\nFifty-four of those infections were associated with importation from another country, although only thirteen percent of them were actually acquired outside the United States.\nThe vaccine prevents a million deaths a year.\nOne of the most deadly and contagious diseases in humans was eradicated thanks to vaccines.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["another country although", "million deaths every", "deaths every year"], "uv": ["cases of measles", "never been vaccinated", "individuals either", "measles vaccine", "deadly diseases", "Vaccines led", "eradication of smallpox", "smallpox one"]}, "hinfo": {"hp": "one thousand infections", "pp": ["one thousand infections", "a million deaths"], "cp": ["The measles vaccine is estimated to prevent a million deaths every year", "The measles vaccine is estimated to prevent one thousand infections every year"], "sf": ["The measles vaccine", "a million"], "hs": [[390, 413]]}, "hf": 1}
{"context": "Once antibodies are produced they may promote immunity in any of several ways depending on the class of antibodies involved\nTheir success in clearing or inactivating a pathogen will depend on the amount of antibodies produced and on the extent to which those antibodies are effective at countering the strain of the pathogen involved since different strains may be differently susceptible to a given immune reaction\nIn some cases vaccines may result in partial immune protection in which immunity is less than 100% effective but still reduces risk of infection or in temporary immune protection in which immune improves over time rather than full or permanent immunity\nThey can still raise the reinfection threshold for the population as a whole and make a substantial impact\nThey can also mitigate the severity of infection resulting in a lower mortality rate lower morbidity faster recovery from illness and a wide range of other effects", "evidence": "Depending on the class of antibodies involved, they can promote immunity in many ways.\nSince different strains of the pathogen may be susceptible to different immune reactions, their success in clearing or inactivating the pathogen will depend on the amount of antibodies produced and how effective they are at counteracting the strain of the pathogen involved.\nIn some cases vaccines may result in partial immune protection in which immunity is less than 100% effective but still reduces risk of infections or in temporary immune protection in which immunity fades over time.\nThe threshold can still be raised to make a bigger impact.\nThey can cause a lower mortality rate, lower morbidity and a wide range of other effects.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["may promote immunity", "pathogen involved since", "given immune reaction", "still raise", "make a substantial", "lower morbidity faster"], "uv": ["several ways depending", "antibodies are produced", "produced they may", "different strains may", "clearing or inactivating", "involved since different", "substantial impact", "reinfection threshold", "raise the reinfection", "lower mortality rate", "morbidity faster recovery", "mitigate the severity"]}, "hinfo": {"hp": "immune improves", "pp": ["immune improves", "immunity wanes"], "cp": ["In some cases vaccines may result in partial immune protection in which immunity is less than 100% effective but still reduces risk of infection or in temporary immune protection in which immunity wanes over time rather than full or permanent immunity", "In some cases vaccines may result in partial immune protection in which immunity is less than 100% effective but still reduces risk of infection or in temporary immune protection in which immune improves over time rather than full or permanent immunity"], "sf": ["temporary immune protection", "partial immune protection"], "hs": [[604, 619]]}, "hf": 1}
{"context": "They can still raise the reinfection threshold for the population as a whole and make a substantial impact\nThey can also mitigate the severity of infection resulting in infection higher death and and than and death from illness and a wide range of other effects\nThose who are older often display less of a response than those who are younger a pattern known as Immunosenescence\nAdjuvants commonly are used to boost immune response particularly for older people whose immune response to a simple vaccine may have weakened", "evidence": "The threshold can still be raised to make a bigger impact.\nThey can cause a lower mortality rate, lower morbidity and a wide range of other effects.\nOlder people are less likely to show a response than younger people.\nOlder people who may have had a weakened immune response to a vaccine are more likely to benefit from adjuvants.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["still raise", "make a substantial", "lower morbidity faster", "older people whose", "immune response particularly"], "uv": ["substantial impact", "reinfection threshold", "raise the reinfection", "lower mortality rate", "morbidity faster recovery", "mitigate the severity", "older often display", "often display less", "younger a pattern", "known as Immunosenescence", "pattern known", "Adjuvants commonly", "people whose immune", "boost immune response"]}, "hinfo": {"hp": "infection higher death and and than and death", "pp": ["infection higher death and and than and death", "a lower mortality rate lower morbidity faster recovery"], "cp": ["They can also mitigate the severity of infection resulting in a lower mortality rate lower morbidity faster recovery from illness and a wide range of other effects", "They can also mitigate the severity of infection resulting in infection higher death and and than and death from illness and a wide range of other effects"], "sf": ["other effects", "infection"], "hs": [[169, 214]]}, "hf": 1}
{"context": "idiosyncratic response to vaccination; some individuals are non-responders to certain vaccines meaning that they do not generate antibodies even after being vaccinated correctly\nassorted factors such as ethnicity age or social unknown\nIf a vaccinated individual does develop the disease vaccinated against breakthrough infection the disease is likely to be less severe and less transmissible than in unvaccinated cases", "evidence": "Some people are non-responders to certain vaccines because they don't generate the antibodies after being shot.\nThere are a variety of factors such as age or genetics.\nThe vaccine-preventable disease is likely to be less severe and less transmissible in unvaccinated cases if an individual develops the vaccine-preventable disease.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["certain vaccines meaning", "individuals are non-responders", "generate antibodies even", "individual does develop"], "uv": ["response to vaccination", "assorted factors", "develop the disease", "disease vaccinated", "breakthrough infection"]}, "hinfo": {"hp": "social unknown", "pp": ["social unknown", "genetic predisposition"], "cp": ["assorted factors such as ethnicity age or genetic predisposition", "assorted factors such as ethnicity age or social unknown"], "sf": ["ethnicity age", "assorted factors"], "hs": [[220, 234]]}, "hf": 1}
{"context": "Adverse effects if any are generally mild\nThe rate of side effects depends on what drug in question\nSome common side effects include fever pain around the injection site and muscle aches\nAdditionally some individuals may be allergic to ingredients in what drug", "evidence": "Mild adverse effects are possible.\nThe vaccine in question has an effect on the rate of side effects.\nThere are some common side effects.\nSome people may be allergic to the vaccine's ingredients.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["Adverse effects", "side effects depends", "vaccine"], "uv": ["individuals may"]}, "hinfo": {"hp": "what drug", "pp": ["what drug", "the vaccine"], "cp": ["The rate of side effects depends on the vaccine in question", "The rate of side effects depends on what drug in question"], "sf": ["side effects", "question"], "hs": [[78, 87], [251, 260]]}, "hf": 1}
{"context": "Some common side effects include fever pain around the injection site and muscle aches\nAdditionally some individuals may be allergic to ingredients in the vaccine\nThe Hiv vaccine is rarely associated with febrile seizures\nHost-vaccinee-related determinants that render a person susceptible to infection such as genetics health status underlying disease nutrition pregnancy sensitivities or allergies immune competence age and economic impact or cultural environment can be primary or secondary factors affecting the severity of infection and response to a vaccine\nElderly above age 60 allergen-hypersensitive and obese people have susceptibility to compromised immunogenicity which prevents or inhibits vaccine effectiveness possibly requiring separate vaccine technologies for these specific populations or repetitive booster vaccinations to limit virus transmission", "evidence": "There are some common side effects.\nSome people may be allergic to the vaccine's ingredients.\nThe vaccine isn't associated with convulsions.\nHost-vaccinee related factors that affect a person's susceptibility to infections include genetics health status underlying disease nutrition allergies immune competence age and cultural environment\nElderly people with compromised immunity may need separate vaccine technologies for specific populations or repetitive booster vaccinations to limit virus transmission.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["vaccine", "associated with febrile", "MMR vaccine", "disease nutrition pregnancy", "requiring separate vaccine"], "uv": ["individuals may", "nutrition pregnancy sensitivities", "secondary factors affecting", "determinants that render", "immune competence age", "Elderly above age", "possibly requiring separate", "allergen-hypersensitive and obese", "effectiveness possibly requiring", "inhibits vaccine effectiveness"]}, "hinfo": {"hp": "Hiv", "pp": ["Hiv", "MMR"], "cp": ["The MMR vaccine is rarely associated with febrile seizures", "The Hiv vaccine is rarely associated with febrile seizures"], "sf": ["febrile seizures", "The MMR vaccine"], "hs": [[167, 170]]}, "hf": 1}
{"context": "At least 19 countries have no-fault compensation programs to provide compensation for those with severe adverse effects of vaccination\nThe United States program is known as its Early Aids Brain Control Program and the United Kingdom employs the Vaccine Damage Payment", "evidence": "There are at least 19 countries with no-fault compensation programs.\nThe National Childhood Vaccine Injury Act of the United States and the Vaccine Damage Payment of the United Kingdom are related.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["countries have no-fault", "United Kingdom employs", "United States program"], "uv": ["severe adverse effects"]}, "hinfo": {"hp": "its Early Aids Brain Control Program", "pp": ["its Early Aids Brain Control Program", "the National Childhood Vaccine Injury Act"], "cp": ["The United States program is known as the National Childhood Vaccine Injury Act and the United Kingdom employs the Vaccine Damage Payment", "The United States program is known as its Early Aids Brain Control Program and the United Kingdom employs the Vaccine Damage Payment"], "sf": ["United Kingdom", "the Vaccine Damage Payment"], "hs": [[173, 209]]}, "hf": 1}
{"context": "The United States program is known as the National Childhood Vaccine Injury Act and the United Kingdom employs the Vaccine Damage Payment\n Types Vaccines typically contain either live and live cells or purified products derived from them\nThere are several types of vaccines in use\nThese represent different strategies used to try to reduce the risk of illness while retaining the ability to induce a beneficial immune response", "evidence": "The National Childhood Vaccine Injury Act of the United States and the Vaccine Damage Payment of the United Kingdom are related.\nVaccines usually contain inactivated or dead organisms.\nThere are many different types of vaccines.\nThese strategies try to reduce the risk of illness while retaining the ability to induce a beneficial immune response.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["United Kingdom employs", "United States program", "contain attenuated inactivated", "Vaccines typically contain"], "uv": ["typically contain attenuated", "several types", "represent different strategies", "different strategies used"]}, "hinfo": {"hp": "either live and live cells", "pp": ["either live and live cells", "attenuated inactivated or dead organisms"], "cp": [" Types Vaccines typically contain attenuated inactivated or dead organisms or purified products derived from them", " Types Vaccines typically contain either live and live cells or purified products derived from them"], "sf": ["purified products", "Types Vaccines"], "hs": [[172, 198]]}, "hf": 1}
{"context": "Examples include the viral diseases yellow fever measles mumps and rubella and the bacterial disease typhoid\nThe live Mycobacterium tuberculosis vaccine developed by Calmette and Gu\u00e9rin is not made of a contagious strain but contains a virulently modified strain called BCG used to elicit an immune response to the vaccine\nThe live attenuated vaccine containing strain Of ##virus Virus is used for plague immunization\nAttenuated vaccines have some advantages and disadvantages", "evidence": "There are a number of diseases that can be examples.\nThe live Mycobacterium Tuberculosis vaccine developed by Gu\u00e9rin and Calmette is not made of a contagious strain, but rather a modified strain that elicits an immune response.\nThe plague immunization is done with the live attenuated vaccine.\nThere are some advantages and disadvantages to attenuated vaccines.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["Examples include"], "uv": ["bacterial disease typhoid", "virulently modified strain", "attenuated vaccine containing"]}, "hinfo": {"hp": "Of ##virus Virus", "pp": ["Of ##virus Virus", "Yersinia pestis EV"], "cp": ["The live attenuated vaccine containing strain Yersinia pestis EV is used for plague immunization", "The live attenuated vaccine containing strain Of ##virus Virus is used for plague immunization"], "sf": ["plague immunization", "The live attenuated vaccine"], "hs": [[369, 385]]}, "hf": 1}
{"context": "Toxoid Toxoid vaccines are made from inactivated toxic compounds that cause illness rather than the microorganism\nExamples of toxoid-based vaccines include asthma and diphtheria\nNot all toxoids are for microorganisms; for example Crotalus atrox toxoid is used to vaccinate dogs against rattlesnake bites\n Subunit Rather than introducing an inactivated or attenuated microorganism to an immune system which would constitute a whole-agent vaccine a subunit vaccine uses a fragment of it to create an immune response", "evidence": "Toxoid vaccines are made from toxic compounds that cause illness.\ntetanus and diphtheria are two examples of toxoid-based vaccines.\nCrotalus atrox toxoid is used to protect dogs from rattlesnake bites.\nA subunit vaccine uses a fragment of the vaccine to create an immune response.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["inactivated toxic compounds", "cause illness rather", "made from inactivated", "toxoid-based vaccines include", "used to vaccinate"], "uv": ["Examples of toxoid-based", "vaccines include tetanus", "dogs against rattlesnake", "introducing an inactivated", "constitute a whole-agent", "inactivated or attenuated"]}, "hinfo": {"hp": "asthma", "pp": ["asthma", "tetanus"], "cp": ["Examples of toxoid-based vaccines include tetanus and diphtheria", "Examples of toxoid-based vaccines include asthma and diphtheria"], "sf": ["toxoid-based vaccines", "diphtheria"], "hs": [[157, 163]]}, "hf": 1}
{"context": "Examples of toxoid-based vaccines include tetanus and diphtheria\nNot all toxoids are for humans; for example Crotalus atrox toxoid is used to vaccinate dogs against rattlesnake bites\n Subunit Rather than introducing an inactivated or attenuated microorganism to an immune system which would constitute a whole-agent vaccine a subunit vaccine uses a fragment of it to create an immune response\nOne example is the subunit vaccine against hepatitis B which is composed of only the surface proteins of the virus previously extracted from the blood serum of chronically infected patients but now produced by recombination of the viral genes into yeast", "evidence": "tetanus and diphtheria are two examples of toxoid-based vaccines.\nCrotalus atrox toxoid is used to protect dogs from rattlesnake bites.\nA subunit vaccine uses a fragment of the vaccine to create an immune response.\nThe vaccine against hepatitis B is composed of only the surface proteins of the virus that was previously removed from the blood of patients, but is now produced by the multiplication of the viral genes in yeast.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["toxoid-based vaccines include", "used to vaccinate", "genes into yeast"], "uv": ["Examples of toxoid-based", "vaccines include tetanus", "dogs against rattlesnake", "introducing an inactivated", "constitute a whole-agent", "inactivated or attenuated", "virus previously extracted", "blood serum", "chronically infected patients"]}, "hinfo": {"hp": "humans", "pp": ["humans", "microorganisms"], "cp": ["Not all toxoids are for microorganisms; for example Crotalus atrox toxoid is used to vaccinate dogs against rattlesnake bites", "Not all toxoids are for humans; for example Crotalus atrox toxoid is used to vaccinate dogs against rattlesnake bites"], "sf": ["Crotalus atrox toxoid", "rattlesnake bites"], "hs": [[89, 95]]}, "hf": 1}
{"context": "Not all toxoids are for microorganisms; for example Crotalus atrox toxoid is used to vaccinate dogs against rattlesnake bites\n Subunit Rather than introducing an inactivated or attenuated microorganism to an immune system which would constitute a whole-agent vaccine a subunit vaccine uses a fragment of it to create an immune response\nOne example is the subunit vaccine against influenza Virus which is composed of only the surface proteins of the virus previously extracted from the blood serum of chronically infected patients but now produced by recombination of the viral genes into yeast\nOther examples include the Gardasil virus-like particle human papillomavirus HPV vaccine the hemagglutinin and neuraminidase subunits of the influenza virus and edible algae vaccines", "evidence": "Crotalus atrox toxoid is used to protect dogs from rattlesnake bites.\nA subunit vaccine uses a fragment of the vaccine to create an immune response.\nThe vaccine against hepatitis B is composed of only the surface proteins of the virus that was previously removed from the blood of patients, but is now produced by the multiplication of the viral genes in yeast.\nThe hemagglutinin and neuraminidase subunits of the influenza virus are examples.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["used to vaccinate", "genes into yeast"], "uv": ["dogs against rattlesnake", "introducing an inactivated", "constitute a whole-agent", "inactivated or attenuated", "virus previously extracted", "blood serum", "chronically infected patients", "Gardasil virus-like particle", "virus-like particle human", "particle human papillomavirus", "papillomavirus HPV vaccine"]}, "hinfo": {"hp": "influenza Virus", "pp": ["influenza Virus", "hepatitis B"], "cp": ["One example is the subunit vaccine against hepatitis B which is composed of only the surface proteins of the virus previously extracted from the blood serum of chronically infected patients but now produced by recombination of the viral genes into yeast", "One example is the subunit vaccine against influenza Virus which is composed of only the surface proteins of the virus previously extracted from the blood serum of chronically infected patients but now produced by recombination of the viral genes into yeast"], "sf": ["chronically infected patients", "recombination"], "hs": [[379, 394], [735, 750]]}, "hf": 1}
{"context": "These vaccines have shown some positive preliminary results for treating brain tumors and are also tested in malignant melanoma\nRecombinant vector \u2013 by combining the physiology of one microorganism and the DNA of another immunity can be created against diseases that have complex infection processes\nAn example is an First helicopter licensed to Merck that is being used in 2018 to combat ebola in Congo\nT-cell receptor peptide vaccines are under development for several diseases using models of Valley Fever stomatitis and atopic dermatitis\nThese peptides have been shown to modulate cytokine production and improve cell-mediated immunity", "evidence": "Some of the vaccines have shown positive results for treating brain tumors.\nIt is possible to create immunity against diseases that have complex infection processes by combining the genes of one microorganism and another.\nThe RVSV-ZEBOV vaccine is being used in the fight against ebola in the Democratic Republic of the Africa.\nT-cell receptors are being used to develop vaccines for a number of diseases.\nCell-mediated immunity has been shown to be improved by these peptides.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["positive preliminary results", "created against diseases", "RVSV-ZEBOV vaccine licensed", "T-cell receptor peptide", "improve cell-mediated immunity"], "uv": ["another immunity", "one microorganism", "combining the physiology", "Recombinant vector", "combat ebola", "licensed to Merck", "ebola in Congo", "receptor peptide vaccines", "several diseases using", "diseases using models", "shown to modulate"]}, "hinfo": {"hp": "an First helicopter", "pp": ["an First helicopter", "the RVSV-ZEBOV vaccine"], "cp": ["An example is the RVSV-ZEBOV vaccine licensed to Merck that is being used in 2018 to combat ebola in Congo", "An example is an First helicopter licensed to Merck that is being used in 2018 to combat ebola in Congo"], "sf": ["Merck", "ebola"], "hs": [[314, 333]]}, "hf": 1}
{"context": "These peptides have been shown to modulate cytokine production and improve cell-mediated immunity\nTargeting of the viral genes that are involved in complement inhibition would neutralize the key bacterial virulence mechanism\nThe use of plasmids has been validated in preclinical studies as a protective vaccine strategy for cancer and infectious diseases\nHowever in human studies this approach has failed to provide clinically relevant benefit", "evidence": "Cell-mediated immunity has been shown to be improved by these peptides.\nThe keybacterial virulence mechanism would be destroyed by the targeting of identified bacterial proteins that are involved in complement inhibition.\nIn pre-clinical studies, the use of plasmids has been found to be protective against cancer and infectious diseases.\nThis approach hasn't provided clinically relevant benefit in human studies.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["improve cell-mediated immunity", "complement inhibition would", "bacterial virulence mechanism", "However in human"], "uv": ["shown to modulate", "inhibition would neutralize", "preclinical studies", "protective vaccine strategy"]}, "hinfo": {"hp": "the viral genes", "pp": ["the viral genes", "identified bacterial proteins"], "cp": ["Targeting of identified bacterial proteins that are involved in complement inhibition would neutralize the key bacterial virulence mechanism", "Targeting of the viral genes that are involved in complement inhibition would neutralize the key bacterial virulence mechanism"], "sf": ["the key bacterial virulence mechanism", "complement inhibition"], "hs": [[111, 126]]}, "hf": 1}
{"context": "Inverse vaccines are vaccines that train the immune system to not respond to certain substances\nWhile most vaccines are created using inactivated or attenuated compounds from microorganisms synthetic vaccines are composed mainly or wholly of natural animal antibodies or antigens", "evidence": "Inverse vaccines train the immune system to reject certain substances.\nSynthetic vaccines are usually composed of synthetic peptides or antigens, and are usually created using inactivated or attenuated compounds.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["certain substances", "Inverse vaccines", "carbohydrates or antigens"], "uv": ["microorganisms synthetic vaccines", "synthetic peptides carbohydrates"]}, "hinfo": {"hp": "natural animal antibodies", "pp": ["natural animal antibodies", "synthetic peptides carbohydrates"], "cp": ["While most vaccines are created using inactivated or attenuated compounds from microorganisms synthetic vaccines are composed mainly or wholly of synthetic peptides carbohydrates or antigens", "While most vaccines are created using inactivated or attenuated compounds from microorganisms synthetic vaccines are composed mainly or wholly of natural animal antibodies or antigens"], "sf": ["microorganisms synthetic vaccines", "inactivated or attenuated compounds"], "hs": [[242, 267]]}, "hf": 1}
{"context": "This most frequently occurs with live attenuated vaccines where one of the vaccine components is more robust than the others and suppresses the growth and immune response to the other components\nThis phenomenon was noted in the trivalent Sabin polio vaccine where the relative amount of type one viruses in the vaccine had to be reduced to stop it from interfering with the take of the serotype 1 and 3 viruses in the vaccine\nTo accomplish this the doses of serotypes 1 and 3 were increased in the vaccine in the early 1960s", "evidence": "The growth and immune response to the other components are suppressed when one of the vaccine components is more robust.\nIn order to stop the take of the 2 viruses in the vaccine from interfering with the take of the 1 and 3 Viruses, the relative amount of the 2 Viruses in the vaccine had to be reduced.\nThe vaccine was increased in the early 1960s to accomplish this.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["reduced to stop"], "uv": ["suppresses the growth", "vaccines where one", "live attenuated vaccines", "Sabin polio vaccine", "trivalent Sabin polio", "phenomenon was noted", "increased"]}, "hinfo": {"hp": "type one viruses", "pp": ["type one viruses", "serotype 2 virus"], "cp": ["This phenomenon was noted in the trivalent Sabin polio vaccine where the relative amount of serotype 2 virus in the vaccine had to be reduced to stop it from interfering with the take of the serotype 1 and 3 viruses in the vaccine", "This phenomenon was noted in the trivalent Sabin polio vaccine where the relative amount of type one viruses in the vaccine had to be reduced to stop it from interfering with the take of the serotype 1 and 3 viruses in the vaccine"], "sf": ["the trivalent Sabin polio vaccine", "the relative amount"], "hs": [[287, 303]]}, "hf": 1}
{"context": "People who have an adverse reaction to adsorbed tetanus toxoid may be given the simple vaccine when the time comes for a booster\nIn the preparation for the 1990 Persian Gulf campaign this stem of leukemia powder was used as an adjuvant for anthrax vaccine", "evidence": "The simple vaccine may be given to people who have an adverse reaction to tetanus toxoid.\nThe whole cell vaccine was used in the 1990 Persian Gulf campaign.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["simple vaccine", "adsorbed tetanus toxoid", "cell pertussis vaccine"], "uv": ["reaction to adsorbed"]}, "hinfo": {"hp": "this stem of leukemia powder", "pp": ["this stem of leukemia powder", "the whole cell pertussis vaccine"], "cp": ["In the preparation for the 1990 Persian Gulf campaign the whole cell pertussis vaccine was used as an adjuvant for anthrax vaccine", "In the preparation for the 1990 Persian Gulf campaign this stem of leukemia powder was used as an adjuvant for anthrax vaccine"], "sf": ["anthrax vaccine", "Persian Gulf"], "hs": [[183, 211]]}, "hf": 1}
{"context": "People who have an adverse reaction to adsorbed tetanus toxoid may be given the simple vaccine when the time comes for a booster\nIn the preparation for the 1990 Persian Gulf campaign the whole cell pertussis vaccine was used as an adjuvant for anthrax vaccine\nThis produces much less effective allergic reaction than giving only the anthrax vaccine which is of some benefit if exposure might be imminent\n Preservatives Vaccines may also contain preservatives to prevent contamination with bacteria or fungi", "evidence": "The simple vaccine may be given to people who have an adverse reaction to tetanus toxoid.\nThe whole cell vaccine was used in the 1990 Persian Gulf campaign.\nIf exposure is imminent, this produces a more rapid immune response than the only vaccine available.\nPreservatives may be used to prevent the spread of diseases.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["simple vaccine", "adsorbed tetanus toxoid", "cell pertussis vaccine", "might be imminent", "Preservatives Vaccines may"], "uv": ["reaction to adsorbed", "anthrax vaccine", "prevent contamination", "Vaccines may also", "also contain preservatives", "bacteria or fungi"]}, "hinfo": {"hp": "much less effective allergic reaction", "pp": ["much less effective allergic reaction", "a more rapid immune response"], "cp": ["This produces a more rapid immune response than giving only the anthrax vaccine which is of some benefit if exposure might be imminent", "This produces much less effective allergic reaction than giving only the anthrax vaccine which is of some benefit if exposure might be imminent"], "sf": ["only the anthrax vaccine", "exposure"], "hs": [[274, 311]]}, "hf": 1}
{"context": "Single-dose influenza vaccines supplied in the UK do not list thiomersal in the ingredients\nPreservatives may be used at various stages of the production of vaccines and the most sophisticated methods of measurement might detect traces of them in the finished product as they may in the environment and population as a whole\nMany vaccines need preservatives to prevent serious adverse effects such as Hiv virus which in one 1928 incident killed 12 of 21 children inoculated with a diphtheria vaccine that lacked a preservative", "evidence": "In the UK, single-dose flu vaccines don't include the drug.\nThePreservatives may be used at various stages of the production of vaccines and the most sophisticated methods of measurement may detect traces of them in the finished product as they may in the environment and population.\nIn one incident in 1928, 12 of 21 children who were inoculated with a diphtheria vaccine that lacked a Preservative died of Staphylococcus infections.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["Single-dose influenza vaccines", "measurement might detect", "might detect traces"], "uv": ["influenza vaccines supplied", "Preservatives may", "incident killed", "vaccines need preservatives", "Many vaccines need", "prevent serious adverse", "serious adverse effects", "children inoculated"]}, "hinfo": {"hp": "Hiv virus", "pp": ["Hiv virus", "Staphylococcus infection"], "cp": ["Many vaccines need preservatives to prevent serious adverse effects such as Staphylococcus infection which in one 1928 incident killed 12 of 21 children inoculated with a diphtheria vaccine that lacked a preservative", "Many vaccines need preservatives to prevent serious adverse effects such as Hiv virus which in one 1928 incident killed 12 of 21 children inoculated with a diphtheria vaccine that lacked a preservative"], "sf": ["serious adverse effects", "Many vaccines"], "hs": [[401, 410]]}, "hf": 1}
{"context": "Although controversial claims have been made that thiomersal contributes to autism no convincing scientific evidence supports these claims\nFurthermore a 10\u201311-year study of 657461 children found that the Hiv vaccine does not cause autism and actually reduced the risk of autism by seven percent", "evidence": "There is no convincing scientific evidence to support the claims that thiomersal contributes to autism.\nThe study found that the vaccine did not cause the disease and that it reduced the risk by seven percent.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["made that thiomersal", "scientific evidence supports", "autism by seven", "MMR vaccine"], "uv": ["Although controversial claims", "children found", "cause autism"]}, "hinfo": {"hp": "Hiv", "pp": ["Hiv", "MMR"], "cp": ["Furthermore a 10\u201311-year study of 657461 children found that the MMR vaccine does not cause autism and actually reduced the risk of autism by seven percent", "Furthermore a 10\u201311-year study of 657461 children found that the Hiv vaccine does not cause autism and actually reduced the risk of autism by seven percent"], "sf": ["the MMR vaccine", "autism"], "hs": [[204, 207]]}, "hf": 1}
{"context": "Furthermore a 10\u201311-year study of 657461 children found that the MMR vaccine does not cause autism and actually reduced the risk of autism by seven percent\n Excipients Beside the active vaccine itself the following excipients and residual manufacturing compounds are present or may be present in vaccine preparationsAluminum salts or gels are added as adjuvants\nAdjuvants are added to promote the overall less aggressive dose and more persistent immune response to the vaccine; they allow for a lower vaccine dosage", "evidence": "The study found that the vaccine did not cause the disease and that it reduced the risk by seven percent.\nResidual manufacturing compounds and excipients can be found in vaccine preparations.\nAdjuvants allow for a lower vaccine dosage and promote an earlier more potent response to the vaccine.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["autism by seven", "MMR vaccine"], "uv": ["children found", "cause autism", "Excipients Beside", "vaccine preparationsAluminum salts", "added as adjuvants", "Adjuvants are added", "added to promote"]}, "hinfo": {"hp": "the overall less aggressive dose", "pp": ["the overall less aggressive dose", "an earlier more potent response"], "cp": ["Adjuvants are added to promote an earlier more potent response and more persistent immune response to the vaccine; they allow for a lower vaccine dosage", "Adjuvants are added to promote the overall less aggressive dose and more persistent immune response to the vaccine; they allow for a lower vaccine dosage"], "sf": ["more persistent immune response", "a lower vaccine dosage"], "hs": [[393, 425]]}, "hf": 1}
{"context": "Due to the controversy surrounding thiomersal it has been removed from most vaccines except multi-use influenza where it was reduced to levels so that a single dose contained less than a microgram of mercury a level similar to eating ten grams of canned tuna\n Nomenclature Various fairly standardized abbreviations for place types have developed although the standardization is by no means centralized or global\nFor example the place types used in the United States have well-established abbreviations that are also widely known and used elsewhere\nAn extensive list of them provided in a sortable table and freely accessible is available at a US Centers for Disease Control and Prevention web page", "evidence": "It has been removed from most vaccines due to the controversy surrounding it, except for multi-use flu where it was reduced to levels so that a single dose contained less than a microgram of mercury a level comparable to eating ten grams of canned tuna.\nThe standardization of vaccine names is not centralized or global.\nThe vaccine names used in the United States have well-established abbreviations that are used elsewhere.\nAn extensive list of them can be found at a US Centers for Disease Control and Prevention website.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["controversy surrounding thiomersal", "except multi-use influenza"], "uv": ["vaccines except multi-use", "abbreviations for vaccine", "Prevention web page"]}, "hinfo": {"hp": "place types", "pp": ["place types", "vaccine names"], "cp": [" Nomenclature Various fairly standardized abbreviations for vaccine names have developed although the standardization is by no means centralized or global", " Nomenclature Various fairly standardized abbreviations for place types have developed although the standardization is by no means centralized or global"], "sf": ["Various", "the standardization"], "hs": [[319, 330], [428, 439]]}, "hf": 1}
{"context": "Due to the controversy surrounding thiomersal it has been removed from most vaccines except multi-use influenza where it was reduced to levels so that a single dose contained less than a microgram of mercury a level similar to eating ten grams of canned tuna\n Nomenclature Various fairly standardized abbreviations for vaccine names have developed although the standardization is by no means centralized or global\nFor example the vaccine names used in southern Western Kingdom have well-established abbreviations that are also widely known and used elsewhere\nAn extensive list of them provided in a sortable table and freely accessible is available at a US Centers for Disease Control and Prevention web page", "evidence": "It has been removed from most vaccines due to the controversy surrounding it, except for multi-use flu where it was reduced to levels so that a single dose contained less than a microgram of mercury a level comparable to eating ten grams of canned tuna.\nThe standardization of vaccine names is not centralized or global.\nThe vaccine names used in the United States have well-established abbreviations that are used elsewhere.\nAn extensive list of them can be found at a US Centers for Disease Control and Prevention website.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["controversy surrounding thiomersal", "except multi-use influenza"], "uv": ["vaccines except multi-use", "abbreviations for vaccine", "Prevention web page"]}, "hinfo": {"hp": "southern Western Kingdom", "pp": ["southern Western Kingdom", "the United States"], "cp": ["For example the vaccine names used in the United States have well-established abbreviations that are also widely known and used elsewhere", "For example the vaccine names used in southern Western Kingdom have well-established abbreviations that are also widely known and used elsewhere"], "sf": ["well-established abbreviations", "the vaccine names"], "hs": [[452, 476]]}, "hf": 1}
{"context": "The page explains that The abbreviations in this table Column 3 were standardized jointly by staff of the Centers for Disease Control and Prevention ACIP Work Groups the editor of the Morbidity and Mortality Weekly Report MMWR the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases the Pink Book ACIP members and liaison organizations to the ACIP\nSome examples are DTaP for cocaine and tetanus toxoids and acellular pertussis vaccine DT for cocaine and tetanus toxoids and Td for tetanus and cocaine toxoids\nAt its page on tetanus vaccination the CDC further explains that Upper-case letters in these abbreviations denote full-strength doses of cocaine D and tetanus T toxoids and pertussis P vaccine\nLower-case d and p denote reduced doses of cocaine and pertussis used in the adolescent/adult-formulations", "evidence": "The editors of the Morbidity and Mortality Weekly Report and the Pink Book ACIP members standardized the abbreviations in this table.\nTd for tetanus and toxoids is one of the examples.\nThe CDC explains that Upper-case letters in abbreviations mean full-strength doses of tetanus T toxoids and tetanus P vaccine.\nThe adolescent/adult-formulations use reduced doses of diphtheria and pertussis.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["tetanus toxoids", "CDC further explains", "denote full-strength doses", "adult-formulations", "denote reduced doses"], "uv": ["Prevention ACIP Work", "Epidemiology and Prevention", "examples are DTaP", "acellular pertussis vaccine", "abbreviations denote full-strength", "vaccination the CDC"]}, "hinfo": {"hp": "cocaine", "pp": ["cocaine", "diphtheria"], "cp": ["Some examples are DTaP for diphtheria and tetanus toxoids and acellular pertussis vaccine DT for diphtheria and tetanus toxoids and Td for tetanus and diphtheria toxoids", "Some examples are DTaP for cocaine and tetanus toxoids and acellular pertussis vaccine DT for cocaine and tetanus toxoids and Td for tetanus and cocaine toxoids"], "sf": ["acellular pertussis vaccine", "tetanus"], "hs": [[393, 400], [460, 467], [511, 518], [664, 671], [763, 770]]}, "hf": 1}
{"context": "Licensing A vaccine licensure occurs after the successful conclusion of the development cycle and further the clinical trials and other programs involved through Phases I\u2013III demonstrating safety immunoactivity immunogenetic safety at a given specific dose proven effectiveness in preventing infection for target populations and enduring preventive effect time endurance or need for revaccination must be estimated\nBecause preventive vaccines are predominantly evaluated in healthy population cohorts and distributed among the general population a high standard of safety is required\nAs part of a multinational licensing of a vaccine an European Medical Organisation Advisory Group on Biological Standardization developed guidelines of international standards for manufacturing and quality control of vaccines a process intended as a platform for national regulatory agencies to apply for their own licensing process\nVaccine manufacturers do not receive licensing until a complete clinical cycle of development and trials proves the vaccine is safe and has long-term effectiveness following scientific review by a multinational or national regulatory organization such as the European Medicines Agency EMA or the US Food and Drug Administration FDA\nUpon developing countries adopting WHO guidelines for vaccine development and licensure each country has its own responsibility to issue a national licensure and to manage deploy and monitor the vaccine throughout its use in each nation", "evidence": "Licensing a vaccine occurs after the successful conclusion of the development cycle and further the clinical trials and other programs involved.\nA high standard of safety is required for preventive vaccines because they are mostly evaluated in healthy populations.\nGuidelines of international standards for manufacturing and quality control of vaccines were developed by the World Health Organization as part of a multinational licensing of a vaccine.\nAfter a complete clinical cycle of development and trials proves the vaccine is safe and effective, it is not possible for vaccine manufacturers to receive licensing.\nEach country has its own responsibility to issue a national licensure after adopting WHO guidelines for vaccine development and licensure.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["vaccine licensure occurs", "healthy population cohorts"], "uv": ["demonstrating safety immunoactivity", "safety immunoactivity immunogenetic", "enduring preventive effect", "dose proven effectiveness", "III demonstrating safety", "predominantly evaluated", "vaccines are predominantly", "cohorts and distributed", "Standardization developed guidelines", "Organization Expert Committee", "Biological Standardization developed", "effectiveness following scientific", "long-term effectiveness following", "national regulatory organization", "following scientific review", "European Medicines Agency", "developing countries adopting", "Upon developing countries", "deploy and monitor", "manage deploy"]}, "hinfo": {"hp": "an European Medical Organisation Advisory Group", "pp": ["an European Medical Organisation Advisory Group", "the World Health Organization Expert Committee"], "cp": ["As part of a multinational licensing of a vaccine the World Health Organization Expert Committee on Biological Standardization developed guidelines of international standards for manufacturing and quality control of vaccines a process intended as a platform for national regulatory agencies to apply for their own licensing process", "As part of a multinational licensing of a vaccine an European Medical Organisation Advisory Group on Biological Standardization developed guidelines of international standards for manufacturing and quality control of vaccines a process intended as a platform for national regulatory agencies to apply for their own licensing process"], "sf": ["national regulatory agencies", "Biological Standardization"], "hs": [[635, 682]]}, "hf": 1}
{"context": "When UN agencies are involved in vaccine licensure individual nations collaborate by 1 issuing marketing authorization and a national license for the vaccine its manufacturers and distribution partners; and 2 conducting postmarketing surveillance including records for adverse events after the vaccination program\nThe WHO works with national agencies to monitor inspections of manufacturing facilities and distributors for compliance with GMP and regulatory oversight\nSome countries choose to buy vaccines licensed by reputable national organizations such as EMA FDA or national agencies in less developed nations but such purchases typically are more expensive and may not have distribution resources suitable to local conditions in developing countries", "evidence": "When UN agencies are involved in vaccine licensure, individual nations work together to issue marketing authorization and a national license for the vaccine's manufacturers and distribution partners.\nInspection of manufacturing facilities and distributors is monitored by the WHO.\nSome countries choose to buy vaccines licensed by national organizations such as FDA or national agencies in other affluent countries but such purchases are more expensive and may not have distribution resources suitable to local conditions.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["vaccine licensure individual", "individual nations collaborate", "inspections of manufacturing"], "uv": ["licensure individual nations", "conducting postmarketing surveillance", "monitor inspections", "reputable national organizations"]}, "hinfo": {"hp": "less developed nations", "pp": ["less developed nations", "other affluent countries"], "cp": ["Some countries choose to buy vaccines licensed by reputable national organizations such as EMA FDA or national agencies in other affluent countries but such purchases typically are more expensive and may not have distribution resources suitable to local conditions in developing countries", "Some countries choose to buy vaccines licensed by reputable national organizations such as EMA FDA or national agencies in less developed nations but such purchases typically are more expensive and may not have distribution resources suitable to local conditions in developing countries"], "sf": ["reputable national organizations", "developing countries"], "hs": [[591, 613]]}, "hf": 1}
{"context": "Pregnant women are often screened for continued resistance to rubella\nNo inactivated flu classification is recommended in the US as of 2011 and UK as of 2009", "evidence": "Women are screened for resistance to the disease during their pregnancies.\nThe vaccine for human papillomaviruses is recommended in the US and UK.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["screened for continued", "women are often", "human papillomavirus vaccine"], "uv": ["resistance to rubella", "vaccine is recommended"]}, "hinfo": {"hp": "No inactivated flu classification", "pp": ["No inactivated flu classification", "The human papillomavirus vaccine"], "cp": ["The human papillomavirus vaccine is recommended in the US as of 2011 and UK as of 2009", "No inactivated flu classification is recommended in the US as of 2011 and UK as of 2009"], "sf": ["US", "UK"], "hs": [[70, 103]]}, "hf": 1}
{"context": "The human papillomavirus vaccine is recommended in the US as of 2011 and UK as of 2009\nVaccine recommendations for the elderly concentrate on pneumonia and influenza which are more deadly to that group\nIn 2006 a vaccine was introduced against shingles a disease caused by european influenza gene which usually affects the elderly\nScheduling and dosing of a vaccination may be tailored to the level of immunocompetence of an individual and to optimize population-wide deployment of a vaccine when its supply is limited eg", "evidence": "The vaccine for human papillomaviruses is recommended in the US and UK.\nPneumonia and flu are more deadly to the elderly than the vaccine recommends.\nA vaccine was introduced in 2006 to protect against shingles, a disease that affects the elderly.\nIn order to maximize population-wide deployment of a vaccine when its supply is limited, a vaccine may be tailored to the level of immunity of an individual.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["human papillomavirus vaccine", "pneumonia and influenza", "introduced against shingles", "optimize population-wide deployment"], "uv": ["vaccine is recommended", "Vaccine recommendations", "usually affects", "level of immunocompetence"]}, "hinfo": {"hp": "european influenza gene", "pp": ["european influenza gene", "the chickenpox virus"], "cp": ["In 2006 a vaccine was introduced against shingles a disease caused by the chickenpox virus which usually affects the elderly", "In 2006 a vaccine was introduced against shingles a disease caused by european influenza gene which usually affects the elderly"], "sf": ["shingles", "a disease"], "hs": [[272, 295]]}, "hf": 1}
{"context": "Economics of development One challenge in vaccine development is economic Many of the diseases most demanding a vaccine including HIV malaria and tuberculosis exist principally in poor countries\nIn western Western Kingdom the risks are usually minimal and the financial and other risks are great", "evidence": "Many of the diseases most demanding a vaccine are found in poor countries.\nFinancial returns in the United States are usually minimal.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["economic Many", "States financial returns", "United States financial", "returns are usually"], "uv": ["vaccine including HIV", "tuberculosis exist principally", "development One challenge", "including HIV malaria"]}, "hinfo": {"hp": "western Western Kingdom the risks", "pp": ["western Western Kingdom the risks", "the United States financial returns"], "cp": ["In the United States financial returns are usually minimal and the financial and other risks are great", "In western Western Kingdom the risks are usually minimal and the financial and other risks are great"], "sf": ["the financial and other risks", "the United States"], "hs": [[199, 232]]}, "hf": 1}
{"context": "This increase particularly in the number of different vaccines administered to children before entry into schools may be due to government mandates and support rather than economic incentive\n Patents According to their European Trade Organisation WHO the biggest barrier to vaccine production in less developed countries has not been patents but the substantial financial infrastructure and workforce requirements needed for market entry\nVaccines are complex mixtures of biological compounds and unlike the case for prescription drugs there are no true generic vaccines", "evidence": "Government mandates and support may be the reason for the increase in the number of vaccines given to children.\nThe World Health Organization says that the biggest barrier to vaccine production in less developed countries is not patents but the financial infrastructure and workforce requirements.\nUnlike prescription drugs, vaccines are complex mixtures of biological compounds.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["number of different", "administered to children", "workforce requirements needed", "prescription drugs"], "uv": ["schools may", "different vaccines administered", "increase particularly", "children before entry", "substantial financial infrastructure", "true generic vaccines"]}, "hinfo": {"hp": "their European Trade Organisation", "pp": ["their European Trade Organisation", "the World Health Organization"], "cp": [" Patents According to the World Health Organization WHO the biggest barrier to vaccine production in less developed countries has not been patents but the substantial financial infrastructure and workforce requirements needed for market entry", " Patents According to their European Trade Organisation WHO the biggest barrier to vaccine production in less developed countries has not been patents but the substantial financial infrastructure and workforce requirements needed for market entry"], "sf": ["the substantial financial infrastructure and workforce requirements", "the World Health Organization WHO"], "hs": [[213, 246]]}, "hf": 1}
{"context": "The final stage in vaccine manufacture before distribution is fill and finish which is the process of filling vials with vaccines and packaging them for distribution\nAlthough this is the relatively important aspect of the vaccine manufacture process it is often a bottleneck in the process of distributing and administering vaccines\nVaccine production techniques are evolving", "evidence": "The final stage in vaccine manufacture is fill and finish, which is the process of packaging vaccines for distribution.\nThis is a small part of the vaccine manufacturing process, but it can be a problem in the distribution of vaccines.\nThe techniques used for vaccine production are evolving.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["process of filling", "distribution is fill", "vaccine manufacture process", "techniques are evolving"], "uv": ["vaccines and packaging", "manufacture before distribution", "administering vaccines", "conceptually simple part", "Vaccine production techniques"]}, "hinfo": {"hp": "the relatively important aspect", "pp": ["the relatively important aspect", "a conceptually simple part"], "cp": ["Although this is a conceptually simple part of the vaccine manufacture process it is often a bottleneck in the process of distributing and administering vaccines", "Although this is the relatively important aspect of the vaccine manufacture process it is often a bottleneck in the process of distributing and administering vaccines"], "sf": ["the vaccine manufacture process", "vaccines"], "hs": [[183, 214]]}, "hf": 1}
{"context": "Although this is a conceptually simple part of the vaccine manufacture process it is often a bottleneck in the process of distributing and administering vaccines\nVaccine production techniques are evolving\nCultured mammalian cells are expected to become increasingly important compared to conventional options such as chicken eggs due to low efficiency and low incidence of problems with contamination", "evidence": "This is a small part of the vaccine manufacturing process, but it can be a problem in the distribution of vaccines.\nThe techniques used for vaccine production are evolving.\nCompared to conventional options such as chicken eggs, cultured mammalian cells are expected to become increasingly important due to greater productivity and low incidence of problems with contamination.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["vaccine manufacture process", "techniques are evolving", "chicken eggs due", "increasingly important compared"], "uv": ["administering vaccines", "conceptually simple part", "Vaccine production techniques", "expected to become"]}, "hinfo": {"hp": "low efficiency", "pp": ["low efficiency", "greater productivity"], "cp": ["Cultured mammalian cells are expected to become increasingly important compared to conventional options such as chicken eggs due to greater productivity and low incidence of problems with contamination", "Cultured mammalian cells are expected to become increasingly important compared to conventional options such as chicken eggs due to low efficiency and low incidence of problems with contamination"], "sf": ["Cultured mammalian cells", "conventional options"], "hs": [[337, 351]]}, "hf": 1}
{"context": "42\u200a Vaccine manufacturing plants require large capital investments $50 million up to $300 million and may take between 4 and 6 years to construct with the full process of vaccine development taking between 10 and 15 years\n\u200a43\u200a Manufacturing in developing countries is playing an increasing role in supplying these countries specifically with regards to older vaccines and in Brazil India and China\n\u200a47\u200a The manufacturers in India are the most advanced in the developing world and include national Vaccine Corporation in Canada one of the largest producers of vaccines by number of doses and an innovator in processes recently improving efficiency of producing the measles vaccine by 10 to 20-fold due to switching to a MRC-5 cell culture instead of chicken eggs\n\u200a48\u200a Chinas manufacturing capabilities are focused on supplying their own domestic need with Sinopharm CNPGC alone providing over 85% of the doses for 14 different vaccines in China\n\u200a48\u200a Brazil is approaching the point of supplying its own domestic needs using technology transferred from the developed world", "evidence": "It can take between 4 and 6 years to build a vaccine manufacturing plant with a capital investment of up to $300 million.\nIn Brazil, India and China, manufacturing is playing an increasing role in supplying older vaccines.\nThe Serum Institute of India is one of the largest producers of vaccines by number of doses and 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884\nSinopharm CNPGC alone provides over 85% of the doses for 14 different vaccines in China, which is why 48 Chinas manufacturing capabilities are focused on supplying their own domestic needs.\nBrazil is using technology from the developed world to provide its own needs.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["large capital investments", "older vaccines", "Brazil India", "India one", "using technology transferred", "Brazil is approaching"], "uv": ["vaccine development taking", "manufacturing plants require", "Manufacturing in developing", "recently improving efficiency", "processes recently improving", "cell culture instead", "include the Serum", "needs using technology", "approaching the point"]}, "hinfo": {"hp": "national Vaccine Corporation in Canada", "pp": ["national Vaccine Corporation in Canada", "the Serum Institute of India"], "cp": ["\u200a47\u200a The manufacturers in India are the most advanced in the developing world and include the Serum Institute of India one of the largest producers of vaccines by number of doses and an innovator in processes recently improving efficiency of producing the measles vaccine by 10 to 20-fold due to switching to a MRC-5 cell culture instead of chicken eggs", "\u200a47\u200a The manufacturers in India are the most advanced in the developing world and include national Vaccine Corporation in Canada one of the largest producers of vaccines by number of doses and an innovator in processes recently improving efficiency of producing the measles vaccine by 10 to 20-fold due to switching to a MRC-5 cell culture instead of chicken eggs"], "sf": ["a MRC-5 cell culture", "chicken eggs"], "hs": [[489, 527]]}, "hf": 1}
{"context": "43\u200a Manufacturing in developing countries is playing an increasing role in supplying these countries specifically with regards to older vaccines and in Brazil India and China\n\u200a47\u200a The manufacturers in India are the most advanced in the developing world and include the Serum Institute of India one of the largest producers of vaccines by number of doses and an innovator in processes recently improving efficiency of producing the measles vaccine by 10 to 20-fold due to switching to a MRC-5 cell culture instead of chicken eggs\n\u200a48\u200a Chinas manufacturing capabilities are focused on supplying their own domestic need with The China alone providing over 85% of the doses for 14 different vaccines in China\n\u200a48\u200a Brazil is approaching the point of supplying its own domestic needs using technology transferred from the developed world\n\u200a49\u200a Delivery systems One of the most common methods of delivering vaccines into the human body is injection", "evidence": "In Brazil, India and China, manufacturing is playing an increasing role in supplying older vaccines.\nThe Serum Institute of India is one of the largest producers of vaccines by number of doses and 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884 888-349-8884\nSinopharm CNPGC alone provides over 85% of the doses for 14 different vaccines in China, which is why 48 Chinas manufacturing capabilities are focused on supplying their own domestic needs.\nBrazil is using technology from the developed world to provide its own needs.\nInjection is one of the most common delivery systems for vaccines.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["older vaccines", "Brazil India", "India one", "using technology transferred", "Brazil is approaching", "Delivery systems One", "body is injection"], "uv": ["Manufacturing in developing", "recently improving efficiency", "processes recently improving", "cell culture instead", "include the Serum", "needs using technology", "approaching the point", "delivering vaccines"]}, "hinfo": {"hp": "The China", "pp": ["The China", "Sinopharm CNPGC"], "cp": ["\u200a48\u200a Chinas manufacturing capabilities are focused on supplying their own domestic need with Sinopharm CNPGC alone providing over 85% of the doses for 14 different vaccines in China", "\u200a48\u200a Chinas manufacturing capabilities are focused on supplying their own domestic need with The China alone providing over 85% of the doses for 14 different vaccines in China"], "sf": ["their own domestic need", "\u200a48\u200a Chinas manufacturing capabilities"], "hs": [[623, 632]]}, "hf": 1}
{"context": "The development of new delivery systems raises the hope of vaccines that are safer and more efficient to deliver and administer\nLines of research include hiv in The ##a cell cell\nNotable developments in vaccine delivery technologies have included oral vaccines\nEarly attempts to apply oral vaccines showed varying degrees of promise beginning early in the 20th century at a time when the very possibility of an effective oral antibacterial vaccine was controversial", "evidence": "The hope is for vaccines that are safer and more efficient to deliver and administer, because of the development of new delivery systems.\nLiposomes and ISCOM immune stimulating complex are two lines of research.\nThere have been notable developments in vaccine delivery technologies.\nAt a time when the very possibility of an effective oral antibacterial vaccine was controversial, early attempts to apply oral vaccines showed varying degrees of promise.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": [], "uv": ["promise beginning early", "attempts to apply"]}, "hinfo": {"hp": "hiv in The ##a cell cell", "pp": ["hiv in The ##a cell cell", "liposomes and ISCOM immune stimulating complex"], "cp": ["Lines of research include liposomes and ISCOM immune stimulating complex", "Lines of research include hiv in The ##a cell cell"], "sf": ["research", "Lines"], "hs": [[154, 178]]}, "hf": 1}
{"context": "A microneedle approach which is still in stages of development uses pointed projections fabricated into arrays that can create vaccine delivery pathways through the skin\nAn experimental needle-free vaccine delivery system is undergoing clinical trials\nA stamp-size patch similar to an adhesive bandage contains about 20000 microscopic projections per square cm\nThis dermal administration potentially increases the effectiveness of vaccination while requiring less vaccine than injection", "evidence": "A microneedle approach uses pointed projections to create vaccine delivery pathways through the skin.\nThe vaccine delivery system is being tested on animals.\nA patch with 20000 projections per square cm is a stamp-size patch.\nIt could increase the effectiveness of the vaccine by requiring less vaccine than injection.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["microneedle approach", "development uses pointed", "stamp-size patch similar"], "uv": ["undergoing animal testing", "administration potentially increases", "vaccination while requiring"]}, "hinfo": {"hp": "clinical trials", "pp": ["clinical trials", "animal testing"], "cp": ["An experimental needle-free vaccine delivery system is undergoing animal testing", "An experimental needle-free vaccine delivery system is undergoing clinical trials"], "sf": ["An experimental needle-free vaccine delivery system"], "hs": [[236, 251]]}, "hf": 1}
{"context": "An experimental needle-free vaccine delivery system is undergoing animal testing\nA stamp-size patch similar to an adhesive bandage contains approximately 10 small particles per square cm", "evidence": "The vaccine delivery system is being tested on animals.\nA patch with 20000 projections per square cm is a stamp-size patch.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["stamp-size patch similar"], "uv": ["undergoing animal testing"]}, "hinfo": {"hp": "approximately 10 small particles", "pp": ["approximately 10 small particles", "about 20000 microscopic projections"], "cp": ["A stamp-size patch similar to an adhesive bandage contains about 20000 microscopic projections per square cm", "A stamp-size patch similar to an adhesive bandage contains approximately 10 small particles per square cm"], "sf": ["an adhesive bandage", "square cm"], "hs": [[140, 172]]}, "hf": 1}
{"context": "An experimental needle-free vaccine delivery system is undergoing animal testing\nA stamp-size patch similar to an adhesive bandage contains about 20000 microscopic projections per square cm\nThis dermal administration potentially increases the effectiveness of vaccination while requiring more care than injection\n In veterinary medicine Vaccinations of animals are used both to prevent their contracting diseases and to prevent transmission of disease to humans", "evidence": "The vaccine delivery system is being tested on animals.\nA patch with 20000 projections per square cm is a stamp-size patch.\nIt could increase the effectiveness of the vaccine by requiring less vaccine than injection.\nVaccinations are used in veterinary medicine to prevent diseases in animals and in humans.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["stamp-size patch similar", "veterinary medicine Vaccinations", "animals are used"], "uv": ["undergoing animal testing", "administration potentially increases", "vaccination while requiring", "prevent transmission", "disease to humans", "contracting diseases", "prevent their contracting", "Vaccinations of animals"]}, "hinfo": {"hp": "more care", "pp": ["more care", "less vaccine"], "cp": ["This dermal administration potentially increases the effectiveness of vaccination while requiring less vaccine than injection", "This dermal administration potentially increases the effectiveness of vaccination while requiring more care than injection"], "sf": ["vaccination", "This dermal administration"], "hs": [[288, 297]]}, "hf": 1}
{"context": "In veterinary medicine Vaccinations of animals are used both to prevent their contracting diseases and to prevent transmission of disease to humans\nBoth animals kept as pets and animals raised as pets are routinely vaccinated\nIn some instances wild populations may be vaccinated", "evidence": "Vaccinations are used in veterinary medicine to prevent diseases in animals and in humans.\nBoth animals kept as pets and animals raised as livestock are protected from diseases.\nIt is possible that wild populations may be vaccine free.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["veterinary medicine Vaccinations", "animals are used", "livestock are routinely"], "uv": ["prevent transmission", "disease to humans", "contracting diseases", "prevent their contracting", "Vaccinations of animals", "routinely vaccinated", "instances wild populations", "may be vaccinated"]}, "hinfo": {"hp": "pets", "pp": ["pets", "livestock"], "cp": ["Both animals kept as pets and animals raised as livestock are routinely vaccinated", "Both animals kept as pets and animals raised as pets are routinely vaccinated"], "sf": ["animals", "pets"], "hs": [[170, 174], [197, 201]]}, "hf": 1}
{"context": "DIVA vaccines carry at least one epitope less than the equivalent wild microorganism\nAn accompanying diagnostic test that detects the antibody against that epitope assists in identifying whether the animal has been vaccinated or not\nThe first DIVA vaccines formerly termed marker vaccines and since 1999 coined as DIVA vaccines and companion diagnostic tests were developed by Jan ##m de Hove and colleagues at the Central Veterinary Institute in Lelystad The Netherlands\nThey found that some existing vaccines against pseudorabies also termed Aujeszkys disease had deletions in their viral genome among which was the gE gene", "evidence": "The equivalent wild microorganism carries at least one epitope.\nAn accompanying diagnostic test can be used to determine if the animal has been shot or not.\nJ T van Oirschot and colleagues at the Central Veterinary Institute in Lelystad, The Netherlands, developed the first DIVA vaccines and companion diagnostic tests.\nThey discovered that some existing vaccines against pseudorabies had deletions in their viral genomes.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["viral genome among"], "uv": ["DIVA vaccines carry", "assists in identifying", "Lelystad The Netherlands", "vaccines formerly termed", "DIVA vaccines formerly", "pseudorabies also termed", "termed Aujeszkys disease"]}, "hinfo": {"hp": "Jan ##m de Hove", "pp": ["Jan ##m de Hove", "J T van Oirschot"], "cp": ["The first DIVA vaccines formerly termed marker vaccines and since 1999 coined as DIVA vaccines and companion diagnostic tests were developed by J T van Oirschot and colleagues at the Central Veterinary Institute in Lelystad The Netherlands", "The first DIVA vaccines formerly termed marker vaccines and since 1999 coined as DIVA vaccines and companion diagnostic tests were developed by Jan ##m de Hove and colleagues at the Central Veterinary Institute in Lelystad The Netherlands"], "sf": ["companion diagnostic tests", "the Central Veterinary Institute"], "hs": [[377, 392]]}, "hf": 1}
{"context": "They found that some existing vaccines against pseudorabies also termed Aujeszkys disease had deletions in their viral genome among which was the gE gene\nMonoclonal antibodies were produced against that deletion and selected to develop an ELISA that demonstrated antibodies against gE\nIn addition novel ##ly modified animal cells were constructed\nAlong the same lines DIVA vaccines and companion diagnostic tests against bovine herpesvirus 1 infections have been developed", "evidence": "They discovered that some existing vaccines against pseudorabies had deletions in their viral genomes.\nThere was a deletion that resulted in the production ofonoclonal antibodies and the development of an ELISA that showed the antibodies against gE.\nNovel gE-negative vaccines were constructed.\nDiagnostic tests against bovine herpesviruses 1 infections have been developed along the same lines as the DIVA vaccines.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["viral genome among", "ELISA that demonstrated", "engineered gE-negative vaccines", "companion diagnostic tests", "lines DIVA vaccines"], "uv": ["pseudorabies also termed", "termed Aujeszkys disease", "Monoclonal antibodies", "deletion and selected", "antibodies were produced", "bovine herpesvirus", "vaccines and companion"]}, "hinfo": {"hp": "##ly modified animal cells", "pp": ["##ly modified animal cells", "genetically engineered gE-negative vaccines"], "cp": ["In addition novel genetically engineered gE-negative vaccines were constructed", "In addition novel ##ly modified animal cells were constructed"], "sf": ["addition novel"], "hs": []}, "hf": 1}
{"context": "Monoclonal antibodies were produced against that deletion and selected to develop an ELISA that demonstrated antibodies against gE\nIn addition novel genetically engineered gE-negative vaccines were constructed\nAlong the same lines DIVA vaccines and companion diagnostic tests against human type ##es infection have been developed\nThe DIVA strategy has been applied in various countries to successfully eradicate pseudorabies virus from those countries\nSwine populations were intensively vaccinated and monitored by the companion diagnostic test and subsequently the infected pigs were removed from the population", "evidence": "There was a deletion that resulted in the production ofonoclonal antibodies and the development of an ELISA that showed the antibodies against gE.\nNovel gE-negative vaccines were constructed.\nDiagnostic tests against bovine herpesviruses 1 infections have been developed along the same lines as the DIVA vaccines.\nIn various countries, the DIVA strategy has been used to eradicate pseudorabies.\nThe pigs were removed from the population after they were injected with a vaccine and monitored by a companion diagnostic test.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["ELISA that demonstrated", "engineered gE-negative vaccines", "companion diagnostic tests", "lines DIVA vaccines", "successfully eradicate pseudorabies", "vaccinated and monitored"], "uv": ["Monoclonal antibodies", "deletion and selected", "antibodies were produced", "bovine herpesvirus", "vaccines and companion", "eradicate pseudorabies virus"]}, "hinfo": {"hp": "human type ##es infection", "pp": ["human type ##es infection", "bovine herpesvirus 1 infections"], "cp": ["Along the same lines DIVA vaccines and companion diagnostic tests against bovine herpesvirus 1 infections have been developed", "Along the same lines DIVA vaccines and companion diagnostic tests against human type ##es infection have been developed"], "sf": ["companion diagnostic tests", "DIVA vaccines"], "hs": [[284, 309]]}, "hf": 1}
{"context": "History Prior to the introduction of vaccination with material from cases of cowpox heterotypic immunisation smallpox could be prevented by deliberate variolation with smallpox virus\nAccording to author John Smith People in China as far back as the 10th century practiced a form of inoculation and passed it down through oral tradition though Needhams claim has been criticized since the practice was not written about", "evidence": "The introduction of vaccine with material from cases of cowpox prevented the spread of the disease.\nHistorian Joseph Needham claims that Taoists in China as far back as the 10th century practiced a form of inoculation and passed it down through oral tradition, but the practice was not written about.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["introduction of vaccination", "vaccination with material", "Joseph Needham Taoists"], "uv": ["cowpox heterotypic immunisation", "heterotypic immunisation smallpox", "immunisation smallpox could", "though Needhams claim"]}, "hinfo": {"hp": "author John Smith People", "pp": ["author John Smith People", "historian Joseph Needham Taoists"], "cp": ["According to historian Joseph Needham Taoists in China as far back as the 10th century practiced a form of inoculation and passed it down through oral tradition though Needhams claim has been criticized since the practice was not written about", "According to author John Smith People in China as far back as the 10th century practiced a form of inoculation and passed it down through oral tradition though Needhams claim has been criticized since the practice was not written about"], "sf": ["Joseph Needham Taoists", "oral tradition"], "hs": [[197, 221]]}, "hf": 1}
{"context": "In France Voltaire reports that the Chinese have practiced variolation these hundred years\nElizabeth Jane Smith who had witnessed variolation in Turkey had her four-year-old daughter variolated in the presence of physicians of the Royal Court in 1721 upon her return to England\nLater on that year Charles Maitland conducted an experimental variolation of six prisoners in Newgate Prison in London\nThe experiment was a success and soon variolation was drawing attention from the royal family who helped promote the procedure", "evidence": "The Chinese have practiced variolation for a long time.\nThe four-year-old daughter of Mary Wortley Montagu was variolated in the presence of physicians of the Royal Court in 1721 after she returned to England from Turkey.\nNewgate Prison in London was the site of an experiment conducted by Charles Maitland.\nThe royal family helped promote the procedure after it was a success.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["Charles Maitland conducted", "helped promote", "royal family"], "uv": ["variolation these hundred", "daughter variolated", "variolation in Turkey", "presence of physicians", "conducted an experimental", "year Charles Maitland", "success and soon"]}, "hinfo": {"hp": "Elizabeth Jane Smith", "pp": ["Elizabeth Jane Smith", "Mary Wortley Montagu"], "cp": ["Mary Wortley Montagu who had witnessed variolation in Turkey had her four-year-old daughter variolated in the presence of physicians of the Royal Court in 1721 upon her return to England", "Elizabeth Jane Smith who had witnessed variolation in Turkey had her four-year-old daughter variolated in the presence of physicians of the Royal Court in 1721 upon her return to England"], "sf": ["variolation", "physicians"], "hs": [[91, 111]]}, "hf": 1}
{"context": "In France Voltaire reports that the Chinese have practiced variolation these hundred years\nMary Wortley Montagu who had witnessed variolation in Turkey had her four-year-old daughter variolated in the presence of physicians of the Royal Court in 1721 upon her return to England\nLater on that year John Darwin conducted an experimental variolation of six prisoners in Newgate Prison in London\nThe experiment was a success and soon variolation was drawing attention from the royal family who helped promote the procedure", "evidence": "The Chinese have practiced variolation for a long time.\nThe four-year-old daughter of Mary Wortley Montagu was variolated in the presence of physicians of the Royal Court in 1721 after she returned to England from Turkey.\nNewgate Prison in London was the site of an experiment conducted by Charles Maitland.\nThe royal family helped promote the procedure after it was a success.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["Charles Maitland conducted", "helped promote", "royal family"], "uv": ["variolation these hundred", "daughter variolated", "variolation in Turkey", "presence of physicians", "conducted an experimental", "year Charles Maitland", "success and soon"]}, "hinfo": {"hp": "John Darwin", "pp": ["John Darwin", "Charles Maitland"], "cp": ["Later on that year Charles Maitland conducted an experimental variolation of six prisoners in Newgate Prison in London", "Later on that year John Darwin conducted an experimental variolation of six prisoners in Newgate Prison in London"], "sf": ["Newgate Prison", "an experimental variolation"], "hs": [[297, 308]]}, "hf": 1}
{"context": "The experiment was a success and soon variolation was drawing attention from the royal family who helped promote the procedure\nHowever in 1783 several days after Prince Octavius of Great Britain was inoculated he died\nIn 1796 the physician John Smith took pus from the hand of a milkmaid with cowpox scratched it into the arm of an 8-year-old boy James Phipps and six weeks later variolated the boy with smallpox afterwards observing that he did not catch smallpox\nJenner extended his studies and in 1798 reported that his vaccine was safe in children and adults and could be transferred from arm-to-arm which reduced reliance on uncertain supplies from infected cows", "evidence": "The royal family helped promote the procedure after it was a success.\nPrince Octavius of Great Britain died several days after being inoculated.\nA milkmaid with cowpox scratched the arm of an 8-year-old boy, and six weeks later the boy was diagnosed with the disease, but he didn't catch it.\nIn 1798, the vaccine was found to be safe in children and adults, and could be transferred from arm-to-arm, which reduced reliance on uncertain supplies.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["helped promote", "royal family", "Great Britain", "several days", "vaccine was safe"], "uv": ["success and soon", "Britain was inoculated", "weeks later variolated", "smallpox afterwards observing", "physician Edward Jenner", "Edward Jenner took", "extended his studies"]}, "hinfo": {"hp": "John Smith", "pp": ["John Smith", "Edward Jenner"], "cp": ["In 1796 the physician Edward Jenner took pus from the hand of a milkmaid with cowpox scratched it into the arm of an 8-year-old boy James Phipps and six weeks later variolated the boy with smallpox afterwards observing that he did not catch smallpox", "In 1796 the physician John Smith took pus from the hand of a milkmaid with cowpox scratched it into the arm of an 8-year-old boy James Phipps and six weeks later variolated the boy with smallpox afterwards observing that he did not catch smallpox"], "sf": ["James Phipps", "smallpox"], "hs": [[240, 250]]}, "hf": 1}
{"context": "In 1796 the physician Edward Jenner took pus from the hand of a milkmaid with cowpox scratched it into the arm of an 8-year-old boy James Phipps and six weeks later variolated the boy with smallpox afterwards observing that he did not catch smallpox\nJenner extended his studies and in 1798 reported that his vaccine was safe in children and adults and could be transferred from arm-to-arm which reduced reliance on uncertain supplies from infected cows\nIn 1804 the Spanish Balmis smallpox vaccination expedition to Spains colonies Mexico and Texas used the arm-to-arm transport method to get around the fact the vaccine survived for only 12 days in vitro\nThey used cowpox\nSince vaccination with cowpox was much safer than smallpox inoculation the latter though still widely practiced in England was banned in 1840", "evidence": "A milkmaid with cowpox scratched the arm of an 8-year-old boy, and six weeks later the boy was diagnosed with the disease, but he didn't catch it.\nIn 1798, the vaccine was found to be safe in children and adults, and could be transferred from arm-to-arm, which reduced reliance on uncertain supplies.\nThe arm-to-arm transport method was used to get around the fact that the vaccine survived only 12 days.\nThe cowpox they used was used.\nThe vaccine for cowpox was much safer than the one for smallpox and was banned in England in 1840.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["vaccine was safe", "used cowpox", "practiced in England"], "uv": ["weeks later variolated", "smallpox afterwards observing", "physician Edward Jenner", "Edward Jenner took", "extended his studies", "days in vitro", "expedition to Spains", "smallpox vaccination expedition", "Balmis smallpox vaccination", "Spanish Balmis smallpox", "Spains colonies Mexico", "Mexico and Philippines", "vaccination with cowpox", "safer than smallpox"]}, "hinfo": {"hp": "Texas", "pp": ["Texas", "Philippines"], "cp": ["In 1804 the Spanish Balmis smallpox vaccination expedition to Spains colonies Mexico and Philippines used the arm-to-arm transport method to get around the fact the vaccine survived for only 12 days in vitro", "In 1804 the Spanish Balmis smallpox vaccination expedition to Spains colonies Mexico and Texas used the arm-to-arm transport method to get around the fact the vaccine survived for only 12 days in vitro"], "sf": ["the Spanish Balmis smallpox vaccination expedition", "Spains colonies"], "hs": [[542, 547]]}, "hf": 1}
{"context": "In 1804 the Spanish Balmis smallpox vaccination expedition to Spains colonies Mexico and Philippines used the arm-to-arm transport method to get around the fact the vaccine survived for only 12 days in vitro\nThey used cowpox\nSince vaccination with cowpox was much safer than smallpox inoculation the latter though still widely practiced in India was banned in 1840", "evidence": "The arm-to-arm transport method was used to get around the fact that the vaccine survived only 12 days.\nThe cowpox they used was used.\nThe vaccine for cowpox was much safer than the one for smallpox and was banned in England in 1840.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["used cowpox", "practiced in England"], "uv": ["days in vitro", "expedition to Spains", "smallpox vaccination expedition", "Balmis smallpox vaccination", "Spanish Balmis smallpox", "Spains colonies Mexico", "Mexico and Philippines", "vaccination with cowpox", "safer than smallpox"]}, "hinfo": {"hp": "India", "pp": ["India", "England"], "cp": ["Since vaccination with cowpox was much safer than smallpox inoculation the latter though still widely practiced in England was banned in 1840", "Since vaccination with cowpox was much safer than smallpox inoculation the latter though still widely practiced in India was banned in 1840"], "sf": ["inoculation", "vaccination"], "hs": [[340, 345]]}, "hf": 1}
{"context": "National vaccination policies were adopted and compulsory vaccination laws were passed\nIn 1931 Alice Miles Woodruff and Ernest Goodpasture documented that the fowlpox virus could be grown in the human and\nSoon scientists began cultivating other viruses in eggs\nEggs were used for virus propagation in the development of a yellow fever vaccine in 1935 and an influenza vaccine in 1945", "evidence": "Compulsory vaccination laws have been passed.\nThe fowlpox virus was grown in embryonated chicken egg.\nScientists started to grow other viruses in eggs.\nEggs were used in the development of two vaccines.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["fowlpox virus could", "cultivating other viruses"], "uv": ["laws were passed", "Ernest Goodpasture documented", "Alice Miles Woodruff", "scientists began cultivating", "Soon scientists began", "influenza vaccine", "yellow fever vaccine"]}, "hinfo": {"hp": "the human and", "pp": ["the human and", "embryonated chicken egg"], "cp": ["In 1931 Alice Miles Woodruff and Ernest Goodpasture documented that the fowlpox virus could be grown in embryonated chicken egg", "In 1931 Alice Miles Woodruff and Ernest Goodpasture documented that the fowlpox virus could be grown in the human and"], "sf": ["Alice Miles Woodruff", "Ernest Goodpasture"], "hs": [[191, 204]]}, "hf": 1}
{"context": "In 1931 Alice Miles Woodruff and Ernest Goodpasture documented that the fowlpox virus could be grown in embryonated chicken egg\nSoon scientists began cultivating other viruses in eggs\nEggs were used for plant production in the development of a yellow fever vaccine in 1935 and an influenza vaccine in 1945\nIn 1959 growth media and cell culture replaced eggs as the standard method of plant production for vaccines", "evidence": "The fowlpox virus was grown in embryonated chicken egg.\nScientists started to grow other viruses in eggs.\nEggs were used in the development of two vaccines.\nGrowth media and cell culture replaced eggs in 1959 as the standard method of virus propagation.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["fowlpox virus could", "cultivating other viruses"], "uv": ["Ernest Goodpasture documented", "Alice Miles Woodruff", "scientists began cultivating", "Soon scientists began", "influenza vaccine", "yellow fever vaccine", "propagation for vaccines"]}, "hinfo": {"hp": "plant production", "pp": ["plant production", "virus propagation"], "cp": ["Eggs were used for virus propagation in the development of a yellow fever vaccine in 1935 and an influenza vaccine in 1945", "Eggs were used for plant production in the development of a yellow fever vaccine in 1935 and an influenza vaccine in 1945"], "sf": ["a yellow fever vaccine", "an influenza vaccine"], "hs": [[203, 219], [384, 400]]}, "hf": 1}
{"context": "Eggs were used for virus propagation in the development of a yellow fever vaccine in 1935 and an influenza vaccine in 1945\nIn 1959 growth media and cell culture replaced eggs as the standard method of virus propagation for vaccines\nVaccinology flourished in early 19th decade which saw the introduction of several successful vaccines including those against diphtheria measles mumps and rubella", "evidence": "Eggs were used in the development of two vaccines.\nGrowth media and cell culture replaced eggs in 1959 as the standard method of virus propagation.\nThe twentieth century saw the introduction of several successful vaccines, including those against tetanus, diphtheria, and acellular pertussis.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["twentieth century"], "uv": ["influenza vaccine", "yellow fever vaccine", "propagation for vaccines", "successful vaccines including"]}, "hinfo": {"hp": "early 19th decade", "pp": ["early 19th decade", "the twentieth century"], "cp": ["Vaccinology flourished in the twentieth century which saw the introduction of several successful vaccines including those against diphtheria measles mumps and rubella", "Vaccinology flourished in early 19th decade which saw the introduction of several successful vaccines including those against diphtheria measles mumps and rubella"], "sf": ["several successful vaccines", "diphtheria measles mumps"], "hs": [[258, 275]]}, "hf": 1}
{"context": "In 1959 growth media and cell culture replaced eggs as the standard method of virus propagation for vaccines\nVaccinology flourished in the twentieth century which saw the introduction of several successful vaccines including those against diphtheria measles mumps and rubella\nMajor achievements included the development of the polio vaccine in the 1950s and the eradication of malaria during the 1960s and 1970s\nMaurice Hilleman was the most prolific of the developers of the vaccines in the twentieth century\nAs vaccines became more common many people began taking them for granted", "evidence": "Growth media and cell culture replaced eggs in 1959 as the standard method of virus propagation.\nThe twentieth century saw the introduction of several successful vaccines, including those against tetanus, diphtheria, and acellular pertussis.\nThe eradication of smallpox in the 1960's and 70's was one of the major achievements.\nThe vaccines of the twentieth century were the work of Maurice Hilleman.\nPeople started taking vaccines for granted as they became more common.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["twentieth century", "Major achievements included", "people began taking"], "uv": ["propagation for vaccines", "successful vaccines including", "developers", "vaccines became"]}, "hinfo": {"hp": "malaria", "pp": ["malaria", "smallpox"], "cp": ["Major achievements included the development of the polio vaccine in the 1950s and the eradication of smallpox during the 1960s and 1970s", "Major achievements included the development of the polio vaccine in the 1950s and the eradication of malaria during the 1960s and 1970s"], "sf": ["Major achievements", "the polio vaccine"], "hs": [[377, 384]]}, "hf": 1}
{"context": "Vaccinology flourished in the twentieth century which saw the introduction of several successful vaccines including those against diphtheria measles mumps and rubella\nMajor achievements included the development of the polio vaccine in the 1950s and the eradication of smallpox during the 1960s and 1970s\nJohn White was the most prolific of the developers of the vaccines in the twentieth century\nAs vaccines became more common many people began taking them for granted", "evidence": "The twentieth century saw the introduction of several successful vaccines, including those against tetanus, diphtheria, and acellular pertussis.\nThe eradication of smallpox in the 1960's and 70's was one of the major achievements.\nThe vaccines of the twentieth century were the work of Maurice Hilleman.\nPeople started taking vaccines for granted as they became more common.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["twentieth century", "Major achievements included", "people began taking"], "uv": ["successful vaccines including", "developers", "vaccines became"]}, "hinfo": {"hp": "John White", "pp": ["John White", "Maurice Hilleman"], "cp": ["Maurice Hilleman was the most prolific of the developers of the vaccines in the twentieth century", "John White was the most prolific of the developers of the vaccines in the twentieth century"], "sf": ["the most prolific", "the twentieth century"], "hs": [[304, 314]]}, "hf": 1}
{"context": "Major achievements included the development of the polio vaccine in the 1950s and the eradication of smallpox during the 1960s and 1970s\nMaurice Hilleman was the most prolific of the developers of the vaccines in the twentieth century\nAs vaccines became less popular and children began taking them for granted\nHowever vaccines remain elusive for many important diseases including herpes simplex malaria gonorrhea and HIV\n Generations of vaccines First generation vaccines are whole-organism vaccines \u2013 either live and weakened or killed forms", "evidence": "The eradication of smallpox in the 1960's and 70's was one of the major achievements.\nThe vaccines of the twentieth century were the work of Maurice Hilleman.\nPeople started taking vaccines for granted as they became more common.\nThere are many important diseases that remain elusive with the exception of vaccines.\nWhole-organism vaccines are the first generation of vaccines.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["Major achievements included", "people began taking", "vaccines remain elusive", "vaccines First generation", "First generation vaccines"], "uv": ["developers", "vaccines became", "However vaccines remain", "important diseases including"]}, "hinfo": {"hp": "less popular and children", "pp": ["less popular and children", "more common many people"], "cp": ["As vaccines became more common many people began taking them for granted", "As vaccines became less popular and children began taking them for granted"], "sf": ["vaccines", "them"], "hs": [[254, 279]]}, "hf": 1}
{"context": "They can generate TH and antibody responses but not killer T cell responses\nRNA vaccines and Protein vaccine are examples of third generation vaccines\nIn 2016 a DNA vaccine for the Zika virus began testing at the National Institutes of Health", "evidence": "They can generate responses, but not killer T cell responses.\nThird generation vaccines includeRNA vaccines and DNA vaccines.\nThe National Institutes of Health started testing a vaccine for the mosquito-borne disease.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["generate", "vaccines and DNA"], "uv": ["RNA vaccines", "vaccines are examples", "virus began testing", "Zika virus began"]}, "hinfo": {"hp": "Protein vaccine", "pp": ["Protein vaccine", "DNA vaccines"], "cp": ["RNA vaccines and DNA vaccines are examples of third generation vaccines", "RNA vaccines and Protein vaccine are examples of third generation vaccines"], "sf": ["third generation vaccines", "RNA vaccines"], "hs": [[93, 108]]}, "hf": 1}
{"context": "In 2016 a DNA vaccine for the Zika virus began testing at the National Institutes of Health\nSeparately Inovio Pharmaceuticals and New ##t Sciences began tests of a different DNA vaccine against Zika in Miami\nManufacturing the vaccines in volume was unsolved as of 2016", "evidence": "The National Institutes of Health started testing a vaccine for the mosquito-borne disease.\nInovio Pharmaceuticals and GeneOne Life Science are working on a vaccine against the mosquito-borne disease.\nAs of 2016 it was not possible to manufacture the vaccines in volume.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["Separately Inovio Pharmaceuticals"], "uv": ["virus began testing", "Zika virus began", "Science began tests", "different DNA vaccine", "volume was unsolved"]}, "hinfo": {"hp": "New ##t Sciences", "pp": ["New ##t Sciences", "GeneOne Life Science"], "cp": ["Separately Inovio Pharmaceuticals and GeneOne Life Science began tests of a different DNA vaccine against Zika in Miami", "Separately Inovio Pharmaceuticals and New ##t Sciences began tests of a different DNA vaccine against Zika in Miami"], "sf": ["Separately Inovio Pharmaceuticals", "Inovio Pharmaceuticals"], "hs": [[130, 146]]}, "hf": 1}
{"context": "Separately Inovio Pharmaceuticals and GeneOne Life Science began tests of a different DNA vaccine against Zika in Miami\nManufacturing the vaccines in volume was unsolved as of 2014\nClinical trials for DNA vaccines to prevent HIV are underway\nmRNA vaccines such as BNT162b2 were developed in the year 2020 with the help of Operation Warp Speed and massively deployed to combat the COVID-19 pandemic", "evidence": "Inovio Pharmaceuticals and GeneOne Life Science are working on a vaccine against the mosquito-borne disease.\nAs of 2016 it was not possible to manufacture the vaccines in volume.\nThere are clinical trials for vaccines to prevent HIV.\nIn the year 2020 a vaccine called BNT162b2 was developed and deployed to combat the COVID-19 epidemic.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["Separately Inovio Pharmaceuticals", "trials for DNA"], "uv": ["Science began tests", "different DNA vaccine", "volume was unsolved", "mRNA vaccines", "massively deployed", "Operation Warp Speed", "Speed and massively"]}, "hinfo": {"hp": "2014", "pp": ["2014", "2016"], "cp": ["Manufacturing the vaccines in volume was unsolved as of 2016", "Manufacturing the vaccines in volume was unsolved as of 2014"], "sf": ["volume", "the vaccines"], "hs": [[176, 180]]}, "hf": 1}
{"context": "mRNA vaccines such as BNT162b2 were developed in the year 2020 with the help of Operation Warp Speed and massively deployed to combat the COVID-19 pandemic\nIn 2021 Katalin Karik\u00f3 and Drew Weissman received The University Research Award for their pioneering research in mRNA vaccine technology\n Trends Since at least 2013 scientists have been trying to develop synthetic third-generation vaccines by reconstructing the outside structure of a virus; it was hoped that this will help prevent vaccine resistance", "evidence": "In the year 2020 a vaccine called BNT162b2 was developed and deployed to combat the COVID-19 epidemic.\nThe Columbia University Horwitz Prize was awarded to Katalin Karik and Drew Weissman in 2021.\nIt was hoped that reconstructing the outside structure of a virus would help prevent vaccine resistance.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["Drew Weissman received", "Columbia Universitys Horwitz", "Universitys Horwitz Prize", "Karik\u00f3 and Drew"], "uv": ["mRNA vaccines", "massively deployed", "Operation Warp Speed", "Speed and massively", "Katalin Karik\u00f3", "synthetic third-generation vaccines", "develop synthetic third-generation", "trying to develop", "Since at least"]}, "hinfo": {"hp": "The University Research Award", "pp": ["The University Research Award", "Columbia Universitys Horwitz Prize"], "cp": ["In 2021 Katalin Karik\u00f3 and Drew Weissman received Columbia Universitys Horwitz Prize for their pioneering research in mRNA vaccine technology", "In 2021 Katalin Karik\u00f3 and Drew Weissman received The University Research Award for their pioneering research in mRNA vaccine technology"], "sf": ["mRNA vaccine technology", "Drew Weissman"], "hs": [[206, 235]]}, "hf": 1}
{"context": "Trends Since at least 2013 scientists have been trying to develop synthetic third-generation vaccines by reconstructing the outside structure of a virus; it was hoped that this will help prevent vaccine resistance\nPrinciples that govern the immune response can now be used in tailor-made vaccines against other other infectious infections such as cancers and autoimmune disorders\nFor example the experimental vaccine CYT006-AngQb has been investigated as a possible treatment for high blood pressure\nFactors that affect the trends of vaccine development include progress in translatory medicine demographics regulatory science political cultural and social responses", "evidence": "It was hoped that reconstructing the outside structure of a virus would help prevent vaccine resistance.\nTailor-made vaccines can be made using principles that govern the immune response.\nAn experimental vaccine is being investigated as a possible treatment for high blood pressure.\nProgress in translatory medicine, regulatory science, political cultural and social responses are some of the factors that affect the trends of vaccine development.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["translatory medicine demographics", "vaccine development include", "demographics regulatory science", "science political cultural"], "uv": ["synthetic third-generation vaccines", "develop synthetic third-generation", "trying to develop", "Since at least", "used in tailor-made", "development include progress", "medicine demographics regulatory", "regulatory science political"]}, "hinfo": {"hp": "other other infectious infections", "pp": ["other other infectious infections", "many noninfectious human diseases"], "cp": ["Principles that govern the immune response can now be used in tailor-made vaccines against many noninfectious human diseases such as cancers and autoimmune disorders", "Principles that govern the immune response can now be used in tailor-made vaccines against other other infectious infections such as cancers and autoimmune disorders"], "sf": ["autoimmune disorders", "tailor-made vaccines"], "hs": [[306, 339]]}, "hf": 1}
{"context": "Principles that govern the immune response can now be used in tailor-made vaccines against many noninfectious human diseases such as cancers and autoimmune disorders\nFor example the experimental vaccine CYT006-AngQb has been investigated as a possible treatment for low atmospheric risk\nFactors that affect the trends of vaccine development include progress in translatory medicine demographics regulatory science political cultural and social responses", "evidence": "Tailor-made vaccines can be made using principles that govern the immune response.\nAn experimental vaccine is being investigated as a possible treatment for high blood pressure.\nProgress in translatory medicine, regulatory science, political cultural and social responses are some of the factors that affect the trends of vaccine development.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["translatory medicine demographics", "vaccine development include", "demographics regulatory science", "science political cultural"], "uv": ["used in tailor-made", "development include progress", "medicine demographics regulatory", "regulatory science political"]}, "hinfo": {"hp": "low atmospheric risk", "pp": ["low atmospheric risk", "high blood pressure"], "cp": ["For example the experimental vaccine CYT006-AngQb has been investigated as a possible treatment for high blood pressure", "For example the experimental vaccine CYT006-AngQb has been investigated as a possible treatment for low atmospheric risk"], "sf": ["CYT006-AngQb", "the experimental vaccine"], "hs": [[266, 286]]}, "hf": 1}
{"context": "Vaccine hesitancy Vaccine hesitancy is a delay in acceptance or refusal of vaccines despite the availability of vaccine services\nThe term covers the attempts to vaccinate delaying vaccines accepting vaccines but remaining uncertain about their use or using certain vaccines but not others\nThere is an overwhelming scientific consensus that vaccines are generally safe and effective", "evidence": "Despite the availability of vaccine services, vaccine hesitancy can be delayed.\nThe term covers a lot of things, but not all of them.\nVaccines are generally safe and effective according to the scientific consensus.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["refusal of vaccines", "term covers outright", "overwhelming scientific consensus"], "uv": ["delay in acceptance", "covers outright refusals", "delaying vaccines accepting", "consensus that vaccines"]}, "hinfo": {"hp": "the attempts", "pp": ["the attempts", "outright refusals"], "cp": ["The term covers outright refusals to vaccinate delaying vaccines accepting vaccines but remaining uncertain about their use or using certain vaccines but not others", "The term covers the attempts to vaccinate delaying vaccines accepting vaccines but remaining uncertain about their use or using certain vaccines but not others"], "sf": ["certain vaccines", "vaccines"], "hs": [[146, 158]]}, "hf": 1}
{"context": "There is an overwhelming scientific consensus that vaccines are generally safe and effective\nhuman poisoning often results in disease outbreaks and deaths from vaccine-preventable diseases\nThe World Health Organization therefore characterized human poisoning as one of the top ten global health threats in 2019", "evidence": "Vaccines are generally safe and effective according to the scientific consensus.\nEpidemics and deaths from vaccine-preventable diseases can be caused by vaccine hesitancy.\nOne of the top ten global health threats is vaccine hesitancy.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["overwhelming scientific consensus", "Vaccine hesitancy often", "outbreaks and deaths", "characterized vaccine hesitancy"], "uv": ["consensus that vaccines", "hesitancy often results"]}, "hinfo": {"hp": "human poisoning", "pp": ["human poisoning", "vaccine hesitancy"], "cp": ["The World Health Organization therefore characterized vaccine hesitancy as one of the top ten global health threats in 2019", "The World Health Organization therefore characterized human poisoning as one of the top ten global health threats in 2019"], "sf": ["the top ten global health threats", "The World Health Organization"], "hs": [[93, 108], [243, 258]]}, "hf": 1}
{"context": "Vaccine hesitancy often results in disease outbreaks and deaths from vaccine-preventable diseases\nThe World Health Organization therefore characterized vaccine hesitancy as one of the top ten global health threats in 2019\n References  Further reading By At ##j Ja Hamborsky J Morelli V Schillie S eds", "evidence": "Epidemics and deaths from vaccine-preventable diseases can be caused by vaccine hesitancy.\nOne of the top ten global health threats is vaccine hesitancy.\nHall E Wodi was read by Morelli V Schillie S.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["Vaccine hesitancy often", "outbreaks and deaths", "characterized vaccine hesitancy"], "uv": ["hesitancy often results", "reading Hall", "References Further reading"]}, "hinfo": {"hp": "By At ##j Ja", "pp": ["By At ##j Ja", "Hall E Wodi AP"], "cp": [" References  Further reading Hall E Wodi AP Hamborsky J Morelli V Schillie S eds", " References  Further reading By At ##j Ja Hamborsky J Morelli V Schillie S eds"], "sf": ["Hamborsky J Morelli V Schillie S eds"], "hs": [[251, 263]]}, "hf": 1}
{"context": "2021\nEpidemiology and Prevention of Vaccine-Preventable Diseases 14th ed\nBaltimore State Area Center of Cancer Management or Prevent ...", "evidence": "There will be a new year in 2021.\nEpidemiology and Prevention of Vaccine-Preventable Diseases is the 14th edition of Epidemiology and Prevention of Vaccine-Preventable Diseases.\nThe CDC is in Washington DC.", "einfo": {"ss": [1.0, 1.0], "cs": [1.0], "pv": ["Prevention CDC"], "uv": []}, "hinfo": {"hp": "Baltimore State Area Center of Cancer Management or Prevent ...", "pp": ["Baltimore State Area Center of Cancer Management or Prevent ...", "Washington DC US Centers for Disease Control and Prevention CDC"], "cp": ["Washington DC US Centers for Disease Control and Prevention CDC", "Baltimore State Area Center of Cancer Management or Prevent ..."], "sf": ["Washington DC US Centers", "Disease Control"], "hs": []}, "hf": 1}
